A survey was carried out among EBMT centres to describe the current practice concerning intrathecal (i.t.) prophylaxis in allogeneic stem cell transplantation for malignant diseases in patients with no central nervous system (CNS) manifestations of the disease at any time. A total of 90 centres reported their practice: 42 centres (47%) never used pre-transplant i.t. prophylaxis as part of the conditioning, whereas 48 centres (53%) gave i.t. prophylaxis to selected groups. The main indications were acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), and lymphoma (53, 33, and 23% of all centres, respectively). Prophylaxis was usually given to all patients with ALL, but often restricted to high-risk patients in AML and lymphoma. Of the 90 centres, 29 (32%) gave prophylactic i.t. treatment after the transplantation, mainly for the same indications as pre-transplant. This survey illustrates the heterogeneity in the current practice of i.t. prophylaxis in allogeneic transplantation for malignant blood disorders in Europe. The documentation in the literature to support the use of i.t. prophylaxis as part of transplantation for malignant diseases in patients without preceding CNS involvement is sparse. Based on the rarity of isolated CNS relapse after allogeneic stem cell transplantation, EBMT does not recommend routine i.t. prophylaxis to patients without prior CNS involvement. In conventional allogeneic stem cell transplantation for malignant diseases, a central aim is to eradicate the malignant cells with the conditioning as completely as possible. As many drugs given intravenously or orally do not reach the central nervous system (CNS) in optimal concentrations, it might be logical to give intrathecal (i.t.) treatment as part of some conditioning regimens. Of the main components of the two most widely used conditioning regimens, total body irradiation (TBI) treats CNS effectively. After intravenous administration of cyclophosphamide, the alkylating activity is much lower in the cerebrospinal fluid than in the plasma, 1,2 whereas busulphan concentrations after oral administration are similar in the plasma and cerebrospinal fluid. Reports in the literature of CNS relapses after allogeneic transplantation and of the effect of i.t. prophylaxis on the CNS relapse rate are rare. We have not found any studies about the efficacy of i.t. prophylaxis pre-transplant as part of the conditioning. In one study, i.t. prophylaxis given after the transplantation was found to prevent CNS relapses in acute lymphoblastic leukaemia (ALL) but not in acute nonlymphoblastic leukaemia, 4 whereas in two other studies no effect on the CNS relapse rate in patients with acute leukaemia was seen. 5, 6 Although the evidence for the usefulness of i.t. prophylaxis given either immediately before the transplantation or post-transplant has been very limited, such prophylaxis has been used since the 1970s. 4 The practice has varied from centre to centre. In order to try to standardize allogeneic transplantation procedures, we carried out a survey among the EBMT centres concerning their i.t. prophylaxis practice in transplant patients with a malignant disease and without preceding CNS manifestations and also performed a literature search on the subject.
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In conventional allogeneic stem cell transplantation for malignant diseases, a central aim is to eradicate the malignant cells with the conditioning as completely as possible. As many drugs given intravenously or orally do not reach the central nervous system (CNS) in optimal concentrations, it might be logical to give intrathecal (i.t.) treatment as part of some conditioning regimens. Of the main components of the two most widely used conditioning regimens, total body irradiation (TBI) treats CNS effectively. After intravenous administration of cyclophosphamide, the alkylating activity is much lower in the cerebrospinal fluid than in the plasma, 1,2 whereas busulphan concentrations after oral administration are similar in the plasma and cerebrospinal fluid. 3 Reports in the literature of CNS relapses after allogeneic transplantation and of the effect of i.t. prophylaxis on the CNS relapse rate are rare. We have not found any studies about the efficacy of i.t. prophylaxis pre-transplant as part of the conditioning. In one study, i.t. prophylaxis given after the transplantation was found to prevent CNS relapses in acute lymphoblastic leukaemia (ALL) but not in acute nonlymphoblastic leukaemia, 4 whereas in two other studies no effect on the CNS relapse rate in patients with acute leukaemia was seen. 5, 6 Although the evidence for the usefulness of i.t. prophylaxis given either immediately before the transplantation or post-transplant has been very limited, such prophylaxis has been used since the 1970s. 4 The practice has varied from centre to centre. In order to try to standardize allogeneic transplantation procedures, we carried out a survey among the EBMT centres concerning their i.t. prophylaxis practice in transplant patients with a malignant disease and without preceding CNS manifestations and also performed a literature search on the subject.
Methods
All EBMT centres were approached and asked to participate in the survey if they were performing allogeneic transplantations. At the time of the survey, in [2001] [2002] , approximately 330 EBMT centres were performing allogeneic transplantations. In total, 90 centres from 21 countries agreed to participate and reported their policy (Appendix A). The questionnaire included questions about i.t. treatment given immediately before the transplantation as part of the conditioning or after the transplantation. The survey was limited to primary prophylaxis, that is, to patients with no CNS manifestations of their malignancy at any time. The centres were asked whether they were giving i.t. prophylaxis as a part of the transplantation procedure, and, if they were, for which indications. The centres were also asked which drugs they used, how many doses were given, and, if methotrexate was used, whether folinic acid was given after the i.t. treatment.
Results
Of the 90 centres, 48 (53%) had the policy to give pretransplant i.t. prophylaxis to selected groups of patients with no CNS involvement at any time, whereas 42 centres (47%) did not give pre-transplant i.t. prophylaxis to any patients. A total of 29 centres (32%) gave i.t. prophylaxis to selected groups of patients after the transplantation. Most of these 29 centres used both pre-and post-transplant i.t. prophylaxis but six centres gave prophylactic i.t. treatment only after the transplantation. No centre used systematic i.t. prophylaxis for all transplant patients with a malignant disease. A total of 36 centres (40%) never gave pre-or posttransplant i.t. prophylaxis to any patients. Table 1 shows the numbers of centres giving routine i.t. prophylaxis and the indications. The most common indication for pre-transplant routine prophylaxis was ALL. All 48 centres that used pre-transplant i.t. prophylaxis gave it to patients with ALL, either to all patients (45 centres) or to selected groups (three centres). Thirty centres, a third of the total, reported to give pre-transplant i.t. prophylaxis to patients with acute myeloid leukaemia (AML), either to all patients (13 centres) or to selected groups (17 centres). In the latter group of centres, the indications for i.t. prophylaxis were mainly FAB-types M4 and M5. Seven centres gave pre-transplant prophylaxis to all lymphoma patients and 14 centres to selected groups, mostly to those with lymphoblastic lymphoma or Burkitt's lymphoma. Two centres reported to give pre-transplant i.t. prophylaxis to all patients with chronic myeloid leukaemia (CML) and 10 to selected groups (patients in accelerated phase or blast crisis). One centre had the policy to give pretransplant prophylaxis to all patients with MDS, and five centres gave i.t. prophylaxis to patients with an excess of blasts only. In two centers, i.t. prophylaxis was given to all patients with chronic lymphatic leukaemia (CLL) and in two others to selected groups. One centre gave pretransplant i.t. prophylaxis to selected myeloma patients.
When pre-transplant i.t. prophylaxis was given, one or two doses were administered. Two paediatric centres reported that the number of doses was dependent on the age. In all cases, methotrexate was used at a dose of 8-15 mg. In 22 of the 48 centres, it was given in combination with 20-50 mg of cytarabine. In two centers, corticosteroid was added to this combination. Six of the 48 centres giving i.t. prophylaxis with methotrexate gave folinic acid after the i.t. treatment.
All 29 centres that used post-transplant i.t. prophylaxis gave this prophylaxis to patients with ALL, most centres to all patients with this diagnosis (Table 1) . In all 18% of the centres gave post-transplant i.t. prophylaxis to AML patients, mostly to selected groups. One centre reported the policy of giving post-transplant i.t. prophylaxis to all lymphoma patients and 12 centres to selected groups. MDS was an indication for post-transplant i.t. prophylaxis in four centres, and CML and CLL in one centre each. I.t. prophylaxis was not given to patients with multiple myeloma after the transplantation in any of the centres. The numbers of the doses of post-transplant i.t. prophylaxis given varied between one and six.
There was no correlation between the centre size (number of transplantations) and the policy to use or not to use i.t. prophylaxis. Of the 12 centres applying one or more rare indications (three or fewer centres in Table 1 ), four were larger and eight smaller than the median centre size. 
Discussion
The present survey describes the current practice concerning i.t. prophylaxis in allogeneic transplantation for malignant blood disorders in European centres. The use of i.t. prophylaxis is highly variable. A total of 60% of the centres reported to give i.t. prophylaxis to some groups of patients, whereas 40% did not use any i.t. prophylaxis. The indications for which i.t. prophylaxis was most commonly given were ALL, AML with monocytic features, and lymphomas. We limited the survey to patients with no CNS manifestations of their malignant blood disease at any time. Giving i.t. treatment as part of the conditioning to patients with previous CNS involvement can be regarded as a kind of consolidation treatment for the CNS disease. The efficacy of i.t. prophylaxis and the indications for it in patients without previous CNS involvement are unclear. To our knowledge there are no reports in the literature about the effectiveness of i.t. prophylaxis given pre-transplant as part of the conditioning. There are three studies evaluating the effect of post-transplant i.t. prophylaxis. In the study by Thompson et al published in 1986 , the overall probability of CNS relapse post-transplant was 13% among 198 patients with ALL and 2% among 217 patients with acute nonlymphoblastic leukaemia. Post-transplant i.t. methotrexate prophylaxis prevented CNS relapses both in ALL patients with previous CNS involvement and in those without it. In patients with acute nonlymphoblastic leukaemia, post-transplant i.t. prophylaxis did not prevent CNS relapses. Ganem et al 5 studied 82 ALL patients transplanted in remission and they concluded that in patients without CNS involvement at diagnosis, transplanted in the first remission with a TBI-containing conditioning regimen, post-transplant prophylactic CNS therapy can be omitted due to the low probability of CNS relapse. Singhal et al 6 found four post-transplant CNS relapses among 329 patients who had been treated with allogeneic transplantation for acute leukaemia in the first remission and had not been given post-transplant i.t. prophylaxis. None of these four patients had had CNS involvement pre-transplant. Systemic relapse had preceded CNS relapse in all four cases, and no isolated CNS relapses were seen. They concluded that routine prophylactic i.t. chemotherapy is not warranted after bone marrow transplantation for acute leukaemia in the first remission.
In view of the very limited documentation of its efficacy, the use of i.t. prophylaxis in a large proportion of centres may be unexpected. This practice probably originates from early conditioning protocols in which i.t. prophylaxis was used.
4 I.t. prophylaxis might be considered appropriate in diseases with a generally high CNS relapse rate, but this is not supported by solid documentation. The observation of a relapse-reducing effect of post-transplant i.t. prophylaxis in ALL reported by Thompson et al 4 in the 1980s may not be fully applicable to the present situation. Chemotherapy preceding the transplantation has evolved since that time, and this may affect the CNS relapse rate after the transplantation.
In patients without prior CNS involvement, the incidence of CNS relapse after allogeneic transplantation is low. 5, 6 There is not enough data available to allow calculations of how many patients should receive i.t. prophylaxis in different diseases to prevent one CNS relapse in case i.t. prophylaxis would be effective, but these numbers would probably be high. However, with the partial exception of one early study, 4 there is no evidence to support the efficacy of i.t. prophylaxis. Prospective randomized studies to evaluate the effect of i.t. prophylaxis could provide an answer but such studies are not feasible in view of the large number of patients required. i.t. treatment is not without risks. It causes discomfort to the patient, headache is common, and there is a risk of leukoencephalopathy [7] [8] [9] and bleeding or hygroma formation. [10] [11] [12] Therefore, based on the evidence presently available, there is no documented indication for routine i.t. prophylaxis as part of allogeneic stem cell transplantation in patients without prior CNS involvement.
Conclusion
The prophylactic use of i.t. chemotherapy as part of conditioning or after the transplantation in patients without preceding CNS involvement is variable in European centres. There is practically no documentation to support such treatment, and i.t. therapy can cause adverse effects. Therefore, based on the data available, EBMT does not recommend routine i.t. prophylaxis, pre-or post-transplant, in allogeneic stem cell transplantation to patients without prior CNS involvement.
